Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from RHHBY

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

MarketBeat

3 Pharma Powerhouses to Watch Closely

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Therefore, it could be wise to keep an eye on top pharma stocks, Roche Holding (RHHBY), Novartis (NVS) and AbbVie (ABBV). Continue reading.

StockNews.com

3 Booming Pharma Stocks Making Waves in the Industry

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Given this backdrop, it could be wise to buy Roche Holding (RHHBY), AstraZeneca (AZN) and Bristol-Myers Squibb (BMY), which look poised for steady returns. Keep reading.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Worried About A Market Meltdown? Then Buy These Stable Stocks Now

The rising inflation and the Fed’s aggressive rate hikes to clamp down on inflation are making investors anxious. Moreover, with analysts expecting multiple interest rate hikes in the coming months, recessionary fears are growing. As the market experiences a bout of volatility, fundamentally solid stocks Johnson & Johnson (JNJ), Roche…

StockNews.com

Bargain-Hunting: 3 Mega-Cap Pharmaceutical Stocks to Buy and Hold

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

StockNews.com

Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients

Roche Holdings AG (OTC:RHHBY) said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease. Crenezumab did not show a statistically significant clinical benefit in its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function. The…

Benzinga

2 Mega-Cap Stocks to Buy on the Dip

Mega-cap stocks Walmart (WMT) and Roche Holding (RHHBY) are both down more than 15% in the past month but could be solid buy the dip candidates.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Roche Releases More Evrysdi Data For Very Young Infants With SMA

Roche Holding AG's (OTC:RHHBY) Genentech has released new long-term data on its oral drug for spinal muscular atrophy (SMA). After three years of treatment, 91% of children who began taking the drug at ages 1-7 months were alive (n=58). In addition, of 48 children evaluated, 32 maintained, and four gained the ability to…

Benzinga

Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials

The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.

Benzinga

EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for Roche Holdings AG's (OTC:RHHBY) mosunetuzumab for relapsed or refractory (R/R) follicular lymphoma (FL). The opinion covers mosunetuzumab for adult patients who have received at least two prior systemic therapies. The CHMP recommendation is based on…

Benzinga

Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis

Genentech, a member of the Roche Holdings AG (OTC:RHHBY), announced new Ocrevus (ocrelizumab) data shows a benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS0 and secondary progressive MS (SPMS). The company noted that 75% of patients achieved no evidence of progression (NEP) in a one-year interim analysis of the…

Benzinga

FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults

The FDA has granted priority review to Roche Holdings AG's (OTC:RHHBY) Actemra/RoActemra (tocilizumab) for COVID-19 in hospitalized adults. "If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for treating COVID-19 in hospitalized patients," Roche said. The Compay also added that more than 1 million people hospitalized with COVID-19 had been treated with Actemra/RoActemra…

Benzinga

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

StockNews.com

Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial

Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population

At the annual congress of the Muscular Dystrophy Association (MDA), Roche Holdings AG (OTC:RHHBY) announced new data for its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). Evrysdi is a novel survival motor neuron 2 (SMN2) splicing modifier, licensed from PTC Therapeutics Inc (NASDAQ:PTCT). At the annual MDA event, Roche’s presentations included new three-year data from the…

Benzinga

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a

Benzinga

Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests

Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.